Syros Pharmaceuticals, Inc. · OTC:SYRS
Syros Pharmaceuticals — Investor Presentation (December 2022)
28 slides from Syros Pharmaceuticals's investor presentation, Dec 12, 2022
Slide 1: An Expression Makes a World of Difference
An Expression Makes a World of Difference December 2022 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical dev
Slide 3: Developing new standards-of-care for frontline hematologic malignancies
SIGNIFICANT MARKET OPPORTUNITIES IN FRONTLINE Targeting patient populations underserved by existing options, which are commercially synergistic MULTIPLE NEAR-TERM CATALYSTS Upcoming opportunities to build momentum and create value, which include pivotal SELECT-MDS-1 data, randomized SELECT-AML-1 dat
Slide 4: Advancing our diversified clinical pipeline
Program Indication Early Clinical IND- Enabling Mid-clinical Pivotal Pivotal Commercial Rights Tamibarotene (oral RARα agonist) Newly diagnosed HR-MDS (w/aza) Newly diagnosed unfit AML (w/ven+aza) SY-2101 (oral ATO) Newly diagnosed APL (w/ATRA) SY-5609 (oral CDK7 inhibitor) Metastatic pancreatic can
Slide 5: Multiple value-driving milestones
PK and safety data Initiation of Phase 3 trial 2H 2023 Multiple value-driving milestones Development candidate named from CDK12 program SY-5609 SY-2101 in APL Tamibarotene in HR-MDS Tamibarotene in AML Pivotal data from SELECT-MDS-1 Phase 3 trial 4Q23/1Q24 Potential NDA filing 2024 Clinical activity
Slide 6: Tamibarotene: Selective oral RAR agonist
Tamibarotene Selective oral RAR agonist
Slide 7: Value of Tamibarotene
Value of Tamibarotene Selective and potent RAR agonist; ~50% of MDS patients and ~30% of AML patients are positive for RARA gene overexpression Clinical development strategy informed by consistent data from multiple trials demonstrating encouraging clinical activity and safety profile Oral drug with
Slide 8: Clinical development strategy reinforced by consistent data from multiple trials
Clinical development strategy reinforced by encouraging, consistent data from multiple trials Single-agent tamibarotene in R/R HR-MDS patients with RARA overexpression showed 60% hematologic response, including one marrow CR1 Phase 2 data evaluating tamibarotene with azacitidine in ND unfit AML pati
Slide 9: High CR rates and durability in Phase 2 trial in unfit AML
High CR rates, rapid onset of action, and clinically meaningful durability in Phase 2 trial* in newly diagnosed unfit AML with RARA overexpression 89% of CRs were deep molecular or cytogenetic CRs Responses seen irrespective of mutation or cytogenetic risk Response rates in patients negative for RAR
Slide 10: Safety profile supports multiple combinations and long-term use
Safety profile supports multiple combinations and long-term use, enhancing opportunity* Generally well-tolerated combination in ND unfit AML patients No increase in neutropenia, anemia and thrombocytopenia compared to single-agent aza Majority of non-hematologic AEs are low grade and reversible *Pha
Slide 11: Ongoing SELECT-MDS-1 Phase 3 trial in HR-MDS
Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS patients with RARA overexpression Robustly designed, double-blind, placebo-controlled study 90% power to detect a difference in CR rates between experimental and control arms 2:1 randomization with one-sided alpha of 0.025 FDA feedback sup
Slide 12: Syros' product candidate targets ~50% of HR-MDS patients
Syros’ Product Candidate Targets ~50% of patients Syros is developing potentially the first therapy for a targeted population in HR-MDS Tamibarotene has the potential to set a new treatment paradigm for HR-MDS patients with RARA overexpression Physicians are familiar with companion diagnostics to de
Slide 13: Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen
Randomized portion of trial* ~80 patients Tamibarotene + venetoclax + azacitidine Venetoclax + azacitidine randomization (1:1) Safety lead-In ~ 6-15 patients Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen (Tami/Ven/Aza) in ND unfit AML patients with RARA overexpression Also evaluating triplet
Slide 14: Safety lead-in of SELECT-AML-1: safety and response summary
Safety Lead-in of SELECT-AML-1 trial: Safety and response summary CR = complete response; CRi = CR with incomplete hematologic recovery; CR/CRi Rate N=6 Median Time to CR/CRi 33 days (range 25–88 days) 50% CRi 33% CR 4/5 patients with CR/CRi had high monocytic expression score (MES) associated wit
Slide 15: Tamibarotene targets one of the largest targeted populations in unfit AML
Tamibarotene targets patients with RARA overexpression which represents one of the largest targeted populations in unfit AML Targeted Populations All Comers Populations ~30% are positive for RARA overexpression LDAC + glasdegib HMA1 + venetoclax XOSPATA® (r/r) FLT3+ TIBSOVO ® IDH1+ IDHIFA® IDH2+ Tar
Slide 16: SY-2101: Novel oral form of arsenic trioxide
SY-2101 Novel oral form of arsenic trioxide
Slide 17: Value of SY-2101
Novel oral form of arsenic trioxide (ATO) with opportunity to replace standard of care for APL patients; APL is approximately 10% of all AML patients Orally bioavailable with exposures consistent with IV ATO Clear development path to approval in front-line APL Potential for rapid adoption in front-l
Slide 18: Clear development path in frontline APL
Clear development path in frontline APL Based on preliminary data as of July 2022 from dose confirmation study: The first cross-over data directly comparing SY-2101 to the approved dose of IV ATO SY-2101 administered at 15 mg achieved exposures comparable to IV ATO administered at 0.15 mg/kg based o
Slide 19: SY-2101 offers opportunity to reduce treatment burden and costs
SY-2101 offers significant opportunity to reduce treatment burden, increase access, reduce health care costs and utilization Current standard of care IV ATO oral ATRA >80% Cure rates Treatment burden: Current course of treatment involves infusions of Market opportunity for an oral therapy: APL accou
Slide 20: SY-5609: Highly selective and potent oral CDK7 inhibitor
SY-5609 Highly selective and potent oral CDK7 inhibitor
Slide 21: SY-5609: Highly selective and potent oral CDK7 inhibitor
Cell Cycle SY-5609: Highly selective and potent oral CDK7 inhibitor SY-5609 is highly selective with subnanomolar potency2 1MTD not yet reached as of October 2022 2Marineau JJ et al, 2021, Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7, J Med Chem Data presented in October 2019 at
Slide 22: Clinical activity in ongoing Phase 1 single agent and combination cohorts
Clinical activity including a confirmed PR and emerging exposure-response relationships in ongoing Phase 1 single agent and combination cohorts *Gemcitabine and nab-paclitaxel administered at approved doses Well tolerated safety profile; MTD has not been reached 30 patients dosed across five levels
Slide 23: Preclinical data support SY-5609 in BRAF-mutant CRC
Preclinical data support SY-5609 in BRAF-mutant CRC in combination with PDL1 inhibitor: SY-5609 part of Roche’s Phase 1/1b INTRINSIC trial 67% (20/30) of models demonstrated ≥ 50% TGI 23% (7/30) demonstrated deep responses of ≥ 90% TGI Deep responses enriched in BRAF-mutant (5/10) models Robust anti
Slide 24: Gene Control Discovery Engine
Gene Control Discovery Engine
Slide 25: Regulatory regions of the genome control gene expression
Previously unexplored regulatory regions of the genome control expression of genes determining cell function; majority of disease variation found in these regions 98% Patient Impact Medicines that control the expression of genes to provide profound benefit for patients with severe diseases Redefinin
Slide 26: Partnered programs and oncology discovery programs
PARTNERED PROGRAMS Program Target Development Drug Discovery IND-enabling Commercial Rights Sickle cell disease & beta thalassemia Myeloproliferative neoplasms Seeking partnerships for our oncology discovery programs ONCOLOGY Program Target Development Drug Discovery IND-enabling Commercial Rights C
Slide 27: Rapidly advancing toward our vision
Rapidly advancing toward our vision Preparing for product launches Commercial company with medicines that provide a profound benefit for cancer patients Advancing late-stage targeted hematology pipeline Capital to fund planned operations into 2025 Now Next Vision
Slide 28: SYR2:S
SYR2:S
Syros Pharmaceuticals — Investor Presentation (December 2022) on 6ix